Evidence map›Paper›PMID 41555219›Full record

ArticleBMC microbiology2026

Lacticaseibacillus rhamnosus LRa05 mitigates DSS-Induced colitis via boosting beneficial gut microbiota and facilitating CD4⁺Foxp3⁺ Treg differentiation.

Jia Dong, Xuxiao Chen, Yuxin Zhang, Yixiang Zhang, Zehua He, Shengning Liang, Xu Cao, Yongquan Li, Wencan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jia Dong *Shanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xuxiao Chen *Department of General Surgery, Hepatobiliary Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yuxin ZhangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yixiang ZhangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Zehua HeShanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Shengning LiangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xu CaoShanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yongquan LiCollege of Horticulture and Landscape Architecture, Zhongkai University of Agriculture and Engineering, Guangzhou, China.
Wencan ZhangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China. wenczhang@sjtu.edu.cn.

Funding

National Natural Science Foundation of China 82373892National Natural Science Foundation of China 82471776
6 · The paper itself

Abstract

backgroundLacticaseibacillus rhamnosus LRa05, originally isolated from infant feces, has been widely used as a probiotic in the food industry. However, its potential as an orally administered probiotic therapeutic for inflammatory bowel disease (IBD) remains underexplored, particularly from an immune regulatory perspective.

resultsIn this study, we demonstrated that administration of LRa05 conferred protective effects in a DSS-induced colitis mouse model. Such protective effects were reflected by attenuated weight loss, preserved colon length, reduced spleen index, and diminished histopathological damage in the colon. Mechanistically, while LRa05 administration exerted minimal impact on the overall microbiota diversity, it altered the species composition. Notably, the abundance of the beneficial bacterium Akkermansia muciniphila was 10-fold higher in LRa05 treated mice compared to controls. This change was thought to further modulate microbial metabolic pathways. More importantly, LRa05 promoted the expansion of CD4⁺Foxp3⁺ Treg cells, as evidenced by a remarkable increase in Treg frequency in both the spleen and mesenteric lymph nodes. Consequently, proinflammatory cytokine levels were reduced, thereby excessive colonic inflammation was suppressed.

conclusionsTaken together, our findings identify LRa05 as a potential therapeutic agent for DSS-induced colitis, with its protective effects mediated through enhancing beneficial gut microbiota and facilitating Treg cell differentiation.

Indexed as

ColitisGastrointestinal MicrobiomeLacticaseibacillus rhamnosusProbioticsT-Lymphocytes, RegulatoryAkkermansiaAnimalsCell DifferentiationColonCytokinesDextran SulfateDisease Models, AnimalFecesForkhead Transcription FactorsMaleMiceCytokinesDextran SulfateForkhead Transcription FactorsFoxp3 protein, mouseAkkermansia muciniphilaColitisInflammationLRa05Treg

Identifiers

PMID41555219
PMCPMC12951993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.